(Total Views: 597)
Posted On: 02/14/2021 11:42:39 PM
Post# of 154011
“That will be a temporary bottleneck.. six months from approval, there will be ample supply for the entire US need.”
That’s very shortsighted of you. Leronlimab demand will be worldwide, not restricted to only the U.S. Therefore, supply will be limited to the severe/critical population for much longer than 6 months. Additionally, the majority of COVID19 patients have mild symptoms and do not experience LH, so insurance isn’t going to approve a $3K drug for everyone diagnosed with COVID19. But what they will pay for is a lab test to identify those at risk to progress to severe/critical and the drug to prevent them from progressing, resulting in billions saved in health care costs.
That’s very shortsighted of you. Leronlimab demand will be worldwide, not restricted to only the U.S. Therefore, supply will be limited to the severe/critical population for much longer than 6 months. Additionally, the majority of COVID19 patients have mild symptoms and do not experience LH, so insurance isn’t going to approve a $3K drug for everyone diagnosed with COVID19. But what they will pay for is a lab test to identify those at risk to progress to severe/critical and the drug to prevent them from progressing, resulting in billions saved in health care costs.
(5)
(1)
